Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03909607 · ClinicalTrials.gov registry record · Phase 4
Nebulized Sub-dissociative Dose Ketamine for Treating Pain
A Phase 4 study, sponsored by Antonios Likourezos.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT03909607 is a Phase 4 study that has completed, run by Antonios Likourezos. The registered enrollment target is 120 participants.
The verdict
NCT03909607, a Phase 4 study, has completed, sponsored by Antonios Likourezos.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
The investigators previous research study comparing the efficacy of intravenous ketamine to morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in emergency department patients. A second study by the investigators showed that increasing the time of administration of the ketamine, from a push injection to a drip infusion, will minimize the adverse effects experienced by recipients of ketamine. The investigators now aim to see if nebulized subdissociative-dose ketamine administered as a single agent in a dose of 1.5 mg/kg via Breath-Actuated Nebulizers (BAN) over 5-15 minutes will provide a better pain relief in comparison to 1 mg/kg and 0.75 mg/kg doses or if the lower doses are equally as effective.
Interventions
- DRUG Ketamine 0.75 mg/kg
- DRUG Ketamine 1.0 mg/kg
- DRUG Ketamine 1.5 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03909607
The ClinicalTrials.gov registry entry for NCT03909607 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antonios Likourezos, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine 0.75 mg/kg is the first listed.
NCT03909607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03909607 about?
NCT03909607 is a clinical study titled "Nebulized Sub-dissociative Dose Ketamine for Treating Pain". The investigators previous research study comparing the efficacy of intravenous ketamine to morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in emergency department patients. A second study by the investigators showed that increasing the time of administration o...
What is the current status of trial NCT03909607?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2019-04-16. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03909607?
The interventions under investigation include: Ketamine 0.75 mg/kg (DRUG), Ketamine 1.0 mg/kg (DRUG), Ketamine 1.5 mg/kg (DRUG).
Who is sponsoring clinical trial NCT03909607?
This trial is sponsored by Antonios Likourezos, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.